Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one
2. Flavopiridol
3. Hmr 1275
4. L 868275
5. L-868275
6. L86-8275
1. Flavopiridol
2. 146426-40-6
3. Alvocidib Freebase
4. L86-8275
5. L 868275
6. L-868275
7. Flavopiridol (alvocidib)
8. Hmr-1275
9. Hmr 1274
10. 131740-09-5
11. L 86-8275
12. 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methylpiperidin-4-yl]-4h-chromen-4-one
13. 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
14. Chembl428690
15. 45ad6x575g
16. 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3s,4r)-3-hydroxy-1-methylpiperidin-4-yl)-4h-chromen-4-one
17. 2-(2-chloro-phenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4h-benzopyran-4-one
18. Nsc 649890 Hcl
19. Mdl-107826a
20. 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methyl-4-piperidyl]chromen-4-one
21. Alvocidib [inn]
22. Flavo
23. Flavoperidol
24. 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methyl-4-piperidinyl]-
25. Alvocidib [usan]
26. L868275
27. Alvocidib [usan:inn]
28. Alvocidibum
29. Unii-45ad6x575g
30. Ccris 9399
31. 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3s,4r)-3-hydroxy-1-methyl-4-piperidinyl)-
32. (-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one
33. Nsc649890
34. 1c8k
35. 1e1y
36. Alvocidib (usan/inn)
37. Flavopiridol [mi]
38. Alvocidib [mart.]
39. Alvocidib [who-dd]
40. Schembl3652
41. Flavopiridol Hcl; Alvocidib
42. Bdbm5655
43. Gtpl5680
44. Chebi:47344
45. Dtxsid20904970
46. Ex-a1901
47. Flavopiridol,alvocidib, Hmr-1275
48. Hmr-1274
49. Mfcd20501884
50. Nsc799330
51. S1230
52. Zinc21288966
53. Am84422
54. Ccg-268666
55. Db03496
56. Nsc-799330
57. (-)-cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one
58. 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3r,4s)-3-hydroxy-1-methyl-4-piperidinyl)-, Rel-(-)-
59. 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, Cis-(-)-
60. As-74761
61. Hy-10005
62. A25160
63. D09868
64. J-008219
65. Q4063441
66. Brd-k87909389-001-01-2
67. (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4h-1-benzopyran-4-one
68. 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3s,4r)-3-hydroxy-1-methylpiperidin-4-yl)-4h-chromen-4-one;alvocidib
69. 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-2,3-dihydro-5,7-dihydroxy-8-[(3s,4r)-3-hydroxy-1-methyl-4-piperidinyl]-
70. 5,7-dihydroxy-2-(2-chlorophenyl)-8-(1-methyl-3beta-hydroxypiperidin-4beta-yl)-4h-1-benzopyran-4-one
Molecular Weight | 401.8 g/mol |
---|---|
Molecular Formula | C21H20ClNO5 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 401.1030004 g/mol |
Monoisotopic Mass | 401.1030004 g/mol |
Topological Polar Surface Area | 90.2 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 628 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Growth Inhibitors
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS). (See all compounds classified as Growth Inhibitors.)
Flavopiridol has known human metabolites that include (2S,3S,4S,5R)-6-[2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Inhibits cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
ABOUT THIS PAGE
A Alvocidib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alvocidib, including repackagers and relabelers. The FDA regulates Alvocidib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alvocidib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alvocidib supplier is an individual or a company that provides Alvocidib active pharmaceutical ingredient (API) or Alvocidib finished formulations upon request. The Alvocidib suppliers may include Alvocidib API manufacturers, exporters, distributors and traders.
click here to find a list of Alvocidib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Alvocidib DMF (Drug Master File) is a document detailing the whole manufacturing process of Alvocidib active pharmaceutical ingredient (API) in detail. Different forms of Alvocidib DMFs exist exist since differing nations have different regulations, such as Alvocidib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Alvocidib DMF submitted to regulatory agencies in the US is known as a USDMF. Alvocidib USDMF includes data on Alvocidib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Alvocidib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Alvocidib suppliers with USDMF on PharmaCompass.
Alvocidib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alvocidib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alvocidib GMP manufacturer or Alvocidib GMP API supplier for your needs.
A Alvocidib CoA (Certificate of Analysis) is a formal document that attests to Alvocidib's compliance with Alvocidib specifications and serves as a tool for batch-level quality control.
Alvocidib CoA mostly includes findings from lab analyses of a specific batch. For each Alvocidib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alvocidib may be tested according to a variety of international standards, such as European Pharmacopoeia (Alvocidib EP), Alvocidib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alvocidib USP).
LOOKING FOR A SUPPLIER?